GlassScriptPhysician profile
Carlee M Cox
NPI 1639762990
$3,983.09
in general payments reported to CMS, 2019-2025
39 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,055 · 2024: $1,209 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968 · Education: $14.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,968.34 |
| Education | $14.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $447.82 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $348.86 | 2023-2025 | |
| Novo Nordisk INC | $246.51 | 2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $203.05 | 2025 | Korlym |
| Ardelyx, INC. | $182.47 | 2023-2025 | Ibsrela |
| Amgen INC. | $147.75 | 2025 | Repatha, Evenity, Tepezza |
| Lilly USA, LLC | $144.63 | 2025 | Mounjaro, Zepbound, Jardiance |
| Regeneron Healthcare Solutions, INC. | $135.94 | 2023-2025 | Dupixent |
| Cequr Corporation | $132.92 | 2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.21 | 2023-2024 | Trulance, Xifaxan |
| Recordati_rare_diseases_inc. | $99.58 | 2025 | Isturisa |
| Gilead Sciences, INC. | $97.50 | 2023-2024 | |
| Madrigal Pharmaceuticals | $96.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $91.22 | 2023-2024 | Stelara, Tremfya, Remicade |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $80.59 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Intercept Pharmaceuticals, INC. | $65.35 | 2023 | Ocaliva |
| Beta Bionics, INC. | $62.06 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $61.80 | 2023-2024 | Dificid |
| Sequel Med Tech, LLC | $52.47 | 2025 | Twiist |
| Phathom Pharmaceuticals, INC. | $46.95 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.75 | 2025 | Jardiance |
| Radius Health, INC. | $33.34 | 2025 | Tymlos |
| Aimmune Therapeutics, INC. | $32.30 | 2024 | |
| Organon LLC | $31.12 | 2024 | |
| Celltrion USA INC. | $28.45 | 2024-2025 | Zymfentra, Vegzelma |
| Neurocrine Biosciences, INC. | $28.15 | 2025 | |
| Xeris Pharmaceuticals, INC. | $24.58 | 2025 | Recorlev |
| Rgh Enterprises LLC | $22.57 | 2025 | |
| Averitas Pharma INC. | $19.98 | 2025 | Qutenza |
| Mannkind Corporation | $19.41 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.34 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.02 | 2025 | |
| Ferring Pharmaceuticals INC. | $17.04 | 2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $16.59 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.41 | 2025 | |
| Pfizer INC. | $14.55 | 2024 | |
| Insulet Corporation | $14.53 | 2025 | Omnipod |
| Medtronic, INC. | $13.72 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlee Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.